Questions across 9 calls

Omkar Kamtekar

Bonanza Portfolio

BLS International Services Limited

BLS International Services Limited CC-Dec23.pdf · 2024-02-13

So, just a clarification to understand if the thought process is right as you said the iDATA acquisition that you have done - the entity is a niche player and it has a higher margins that's what BLS has. So, I think by what time you will be able to complete the acquisition because if it is a higher margin business, once that becomes incorporated in the numbers of BLS, the margin from the visa services should increase and if you are saying that the visa margin we are currently at 20, they could jump higher. So, would that be a material jump or a normal jump?

Understood sir, but would the margins jump materially higher or would be it incremental marginal gain? So, would it be say for example if the margin is currently 20%. Would it go like 25-26-27 percent would be like 1 or 2% higher? It's just that would it be a material jump or a normal jump?

Divi's Laboratories Limited

Divi's Laboratories Limited CC-Dec23.pdf · 2024-02-10

First a clarification. What was the number that you quoted for the nutraceutical business, the revenue generated from the nutraceuticals business?

The question was with respect to the asset turn s. Currently, the Kakinada block is approximately Rs. 450 odd crores and the total gross block as at the end of FY23 was Rs. 6000 odd crores. Currently, we are at close to 1.2x to 1.3x sales to gross block. How are we looking to ramp it up? Because historically we have been at 1.5x, currently we are at lower. So, how far materially higher will this asset turn increase? And as you said in the previous question’s answer that we will be looking to add capacity as and when the opportunities come. So, with that being said, could we say that we could reach close to Rs. 10,000 crores top line by the next 2-3 years if we ramp up taking into factor both the increase in the asset turns and the capacity?

Piramal Pharma Limited

Piramal Pharma Limited CC-Dec23.pdf · 2024-01-31

So, firstly, what I wanted to ask was with respe ct to the consumer health care business, Power brands approximately contribute 41% of our revenues for the nine months FY'24, i t's been steady. How do you see th ese numbers going to meaningfully move ahead and higher , what is the outlook there?

So, any of the non-other brands that could migrate into the power brands, is there something like that could happen over the medium term, near term, could that be, could that be also a case?

Piramal Pharma Limited CC-Sep23.pdf · 2023-10-30

I just wanted to have , so this is part of the a sset turns. Can you give us a blended capacity utilization? Is that possible?

Home First Finance Company India Limited

Home First Finance Company India Limited CC-Dec23.pdf · 2024-01-19

One of the questions was in regard to the leverage. So, you said you're comfortable to go up to 5.5x - 6x leverage. So, it would be assumed that by FY26 if we hit a leverage of say 5.5x and the ROA remains same, so our RoE would be much higher. So, our R OEs could be closer into the 20%. Would that be fair assumption then?

Okay, so if we take it at 5x, then it makes sense. And also, will there be an equity raise required by the firm? Do you see a need for an equity raise to happen in the near future?

Home First Finance Company India Limited CC-Sep23.pdf · 2023-10-27

Can we have a bifurcation to understand is there a specific bucket size of a specific ticket size, seeing more growth. So, say, for example, is the two million to 2.5 million having a higher disbursed sales than a one million to 1.5 million, is there -- can we see some change in there? Are we seeing some trends there?

Okay. And with respect to the cost of borrowing, our current cost of borrowings as for H1, it's standing at 8.1%. The incremental cost of borrowings, what would be that if we can have some colour on that on going forward?

CREDITACCESS GRAMEEN LIMITED

CREDITACCESS GRAMEEN LIMITED CC-Dec23.pdf · 2024-01-19

So, the first question is with respect to the core banking system upgrade that we have upgraded. So technically speaking, with this update, we will be effectively a bank at scale and technology. Would that be a fair assumption?

Okay. So, in effect, we are a MFI banking company. And with respect to that, then we are also planning to expand ourselves, our presence in other locations and the branch additions that we have made, we have added 17 -odd branches in the quarter and over 100 branches in the 9 months. So incrementally, how are we looking to expand? Are we looking to expand in geographies that we are not present or we are further going deeper into the existing geographies? How is the branch addition going to look ahead?

CREDITACCESS GRAMEEN LIMITED CC-Sep23.pdf · 2023-10-20

Thank you for taking my question. Firstly, the end of it was previously answered but just to get a proper understanding even in the guidance we have said that NIMs have expanded because we have used internal accruals and own funds for growth so therefore in the near term I think we may not requ ire any e xternal funding so I think INR 990 Crore that we raised I think would be fair enough for the year.

Sure. Thank you for the clarification. I need growth guidance or maybe color f rom you in the GLP product mix segment the home improvement and the retail segment have shown good growth so the home improvement has almost doubled and retail finance has almost increased by 60% on a year-on-year basis, the growth has been more so ramped up since Q4, Q1 and Q2 so do we see this ra mping up and also the average amount per loan is also increasing for both . Could we please give us an understanding of how much can go up to as a part of the entire portfolio and will this be margin accretive?

Krishna Institute of Medical Sciences Limited

Krishna Institute of Medical Sciences Limited CC-Sep23.pdf · 2023-11-08

Q2?

Okay. We have seen that the ARPOB has marginally declined despite the volumes being increasing in some of the facilities, so any specific reason generally because of the monsoon period, the Q2 is a period where you generally see a lot more diseases and people getting admitted for various reasons, so any reasons for specifically for the ARPOB to marginally decline?